Global Market Study on Uterine Cancer Diagnostic Testing: Endometrium Carcinoma Segment to Lead in Terms of Value Through 2026


Uterine Cancer Diagnostic Testing  Market
  • Published On : Sep-2018 |
  • Pages : 241 Pages |
  • Format :

Persistence Market Research offers an eight year forecast on the global Uterine Cancer Diagnostic Testing market. The primary objective of the report is to offer updates and information related to market opportunities in the Uterine Cancer Diagnostic Testing market.

Report Description

In terms of revenue, the global Uterine Cancer Diagnostic Testing market is expected to register a CAGR of 7.8% during the forecast period, 2018–2026. The primary objective of the report is to offer insights on the market dynamics that can influence the growth of the global Uterine Cancer Diagnostic Testing market over the forecast period. Insights on key trends, drivers, restraints, value forecasts and opportunities for companies operating in the global Uterine Cancer Diagnostic Testing market are presented in the report.

The global market for Uterine Cancer Diagnostic Testing is expected to witness high growth rate in terms of value in high economic countries due to increase in incidence of uterine cancer cases and efficient healthcare infrastructure. Increase in healthcare expenditure and rising women geriatric population has also driven the market for Uterine Cancer Diagnostic Testing. Low and Middle economy countries like India and South Africa have a lower incidence rate for uterine cancer. The diagnosis rate is poor in these countries and thus, these countries witness low growth rate in terms of value for Uterine Cancer Diagnostic Testing market.

The report includes Uterine Cancer Diagnostic Test types like ultrasound scanning, biopsy procedures and blood tests. Ultrasound scanning has further been segmented into abdominal ultrasound scanning and transvaginal ultrasound scanning. Biopsy procedures include endometrial biopsy, hysteroscopy and dilation & curettage. Blood tests include a complete blood count test, also known as CBC and CA125 marker blood test.

However, the report does not include revenue generated by the imaging procedures like CT scans, MRI scans, X-Rays, PET scans, endoscopy procedures and other screening & treatment methods. Currency fluctuations and inflation are not considered while calculating the revenue of the Uterine Cancer Diagnostic Testing market.

Revenue from the Uterine Cancer Diagnostic Testing market in North America is expected to expand at a relatively higher CAGR due to growing awareness of women health and gynaecologic cancer. High incidence rates also contribute to the market for Uterine Cancer Diagnostic Testing in the region. To understand and assess the opportunities in this market, the report offers the market forecast on the basis of segment type classified into the cancer type, diagnostic test type, end users and regions. The report provides analysis of the global Uterine Cancer Diagnostic Testing market in terms of market value (US$ Mn).

The global Uterine Cancer Diagnostic Testing market is segmented on the basis of cancer type into:

  • Endometrial Carcinoma
  • Uterine Sarcoma

The report begins with the market definition of Uterine Cancer Diagnostic Testing, followed by definitions of different cancer and diagnostic test types. The market dynamics section includes PMR’s analysis on key trends, drivers, restraints, opportunities, macro-economic factors and reimbursement scenario influencing the growth of the global Uterine Cancer Diagnostic Testing market.

The report analyses the Uterine Cancer Diagnostic Testing market on the basis of diagnostic test type and end users and presents forecast in terms of value for the next 8 years. On the basis of diagnostic test type, the global Uterine Cancer Diagnostic Testing market is segmented into:

  • Ultrasound Scanning
    • Abdominal Ultrasound Scanning
    • Transvaginal Ultrasound Scanning
  • Biopsy Procedures
    • Endometrial Biopsy
    • Hysteroscopy
    • Dilation & Curettage
  • Blood Tests
    • Complete Blood Count
    • CA125 Marker Blood Test

On the basis of the end users, the global Uterine Cancer Diagnostic Testing market is segmented into:

  • Hospitals
  • Ambulatory Surgical Centers
  • Cancer Research Institutes
  • Specialized Clinics
  • Diagnostic Laboratories
  • Others

Next, the report analyses the market on the basis of regions and presents forecast in terms of value for the next 8 years. On the basis of region, the global Uterine Cancer Diagnostic Testing market is segmented into:

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Poland
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific excluding China
    • India
    • China
    • Australia & New Zealand
    • ASEAN
    • Rest of Asia- Pacific excluding China
  • China
  • Middle East & Africa (MEA)
    • Saudi Arabia
    • South Africa
    • Rest of Middle East and Africa

In addition, we have considered Year-on-Year (Y-o-Y) growth to understand the predictability of the market and identify growth opportunities for companies operating in the global Uterine Cancer Diagnostic Testing market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is usually overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective for services offered by the Uterine Cancer Diagnostic Testing market. To understand the key segments in terms of their growth and performance in the global Uterine Cancer Diagnostic Testing market, Persistence Market Research has developed a market attractiveness index. The resulting index will help identify the existing market opportunities in Uterine Cancer Diagnostic Testing market.

In the final section of the report, a ‘competitive landscape’ has been included to provide a dashboard view of the key companies operating in the global Uterine Cancer Diagnostic Testing market. This section is primarily designed to provide clients with an objective and detailed comparative assessment of the key providers specific to a market segment in the Uterine Cancer Diagnostic Testing market. However, this section also includes market strategies and SWOT analysis of the key players operating in the global Uterine Cancer Diagnostic Testing market.

Detailed profiles of Uterine Cancer Diagnostic Testing drug manufacturers are also included in the scope of the report to evaluate their long- and short-term strategies. Examples of some of the key players operating in the Uterine Cancer Diagnostic Testing market are Abbott, Roche Holdings AG, Siemens, Danaher and Biomerieux SA.

Uterus a female organ also referred as the womb is located in the lower abdomen. It supports in the fetal development until birth. Uterine cancer is the malignant growth of cells comprised of uterine tissues. Uterine cancer is of two types, namely endometrial carcinoma and uterine sarcoma. Endometrial carcinoma generally occurs in the lining of the uterus, also called as the endometrium, whereas uterine sarcoma develops in the supporting network of the uterus such as tissues, bones and muscles associated with the uterus. The risk associated with the development of uterine cancer includes hyperplasia mostly in women who have never borne a child, obese women, and due to excessive intake of treatment drugs for breast cancer. Endometrial carcinoma is symptomatic in behavior and the major symptoms include abnormal bleeding from the vagina, pelvic pain or abrupt vaginal discharge. Unlike endometrial carcinoma, uterine sarcoma is asymptomatic in behavior and is diagnosed at later stages.

The uterine cancer diagnostic testing includes ultrasound scanning, biopsy procedures and blood tests. The ultrasound scanning tests use sound waves and generate images of the ovaries and the uterus. Two types of ultrasound scannings are involved with uterine cancer diagnostic testing, abdominal ultrasound scanning and transvaginal ultrasound scanning. The abdominal scanning test includes scanning of a filled bladder across the abdomen with the help of a small device called transducer, whereas in transvaginal scanning a transducer wand is inserted in the vagina to scan or create an image. Biopsy procedures involve endometrial biopsy, hysteroscopy and dilation & curettage. Endometrial biopsy involves removal of some malignant tissues from the organ and sending it for a sampling procedure. In hysteroscopy, a small telescope like device is inserted through the vagina in the uterus to capture an image. Dilation & curettage is a conventional method which involves dilation of the cervix and insertion of a small microscope in the vagina. Endometrial biopsy and D&C is generally combined with a hysteroscopy procedure. Blood tests are done to assess general health and further for diagnosis of uterine cancer. Complete blood count is the first line of diagnosis because it helps to analyze the hormone level elevations. CA125 is a tumor marker blood test that specifically measures CA125 levels in the blood. CA125 is a glycoprotein and is also a tumor marker. The first line of diagnosis includes blood test and ultrasound scanning. Confirmatory tests include biopsy procedures.

In terms of revenue, the global uterine cancer diagnostic testing market is projected to expand at a CAGR of 7.8% during the forecast period and is expected to be valued at US$ 3,756.8 Mn by the end of 2026. Asia-Pacific market for uterine cancer diagnostic testing is expected to witness siginificant growth in the global uterine cancer diagnostic testing market over the forecast period.

The global uterine cancer diagnostic testing market is segmented into six major regions, namely North America, Latin America, Europe, Asia Pacific (Asia-Pacific excluding China), China and Middle East & Africa (MEA). In terms of value, North America market for uterine cancer diagnostic testing is expected to be the dominant regional market for uterine cancer diagnostic testing by 2018 end and is expected to expand at a CAGR of 5.7% over the forecast period. Europe, Asia Pacific and China market for uterine cancer diagnostic testing are expected to be the fast-growing markets in terms of revenue in the global uterine cancer diagnostic testing market, registering CAGRs of 8.9%, 12.2% and 11.0%, respectively, over the forecast period.

uterine cancer diagnostic testing market

In North America, the U.S. is expected to be the dominant market for uterine cancer diagnostic testing due to growing incidence of uterine cancer. According to the National Institutes of Health, the U.S. had a high incidence of uterine cancer becasuse of the growing obese population due to unhealthy lifestyles, and rise in the number of post-menopausal women population. Availability of cost-effective diagnosis and treatment options for uterine cancer diagnostic testing is also a factor expected to drive the growth of the market for uterine cancer diagnostic testing in the U.S. over the forecast period. Growing women geriatric population in the U.S. is also a major factor contributing to the growth of the uterine cancer diagnostic testing market. According to the U.S. Census Bureau, in 2012, women aged 65 and above accounted for around 56.4% of total elderly population in the U.S. Besides, according to the 2017 world population statistics, in the window of women aged between 25 and 99 years, 52.9% women belonged to the age group of 50–99 years in the U.S. The U.S. has just shifted to the in-office physician services and at certain crux of this shift, there is a 237% increment in the in-office physician services for hysteroscopy and endometrial sampling, owing to the increase in reimbursements.

The second dominant market for uterine cancer diagnostic testing is China due to an increase in healthcare expenditure and funding by the government. The reimbursement policies by the government for women health screenings and treatment are also expected to drive the growth of the market for uterine cancer diagnostic testing in China. With a large population as well as growing post-menopausal women population demand for a higher scope of diagnosis. According to the data from the National Central Cancer Registry of China (NCCR), the mortality and incidence of cancer has been rapidly growing, where uterine cancer is the second most common type of gynecologic cancer in China.

The number of uterine cancer cases are also increasing in Europe, which is expected to drive the growth of the market for uterine cancer diagnostic testing in the region. According to the statistics provided by the European Society for Medical Oncology, approximately 7,400 new cases are registered in the U.K. and 88,068 in the European Union every year. Also, according to the Cancer Registry of Norway, in 20 gynecologic cancer cases, more than 1 is of endometrial cancer. Increase in healthcare expenditure is also expected to drive the growth of the Europe market for uterine cancer diagnostic testing over the forecast period.

Company Profiles 

  • Abbott
  • Roche Holdings AG
  • Siemens AG
  • Danaher
  • BioMerieux SA
  • Others
Back To Top